| 0.6284 0.076 (13.76%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.82 | 1-year : | 0.96 |
| Resists | First : | 0.7 | Second : | 0.82 |
| Pivot price | 0.49 |
|||
| Supports | First : | 0.47 | Second : | 0.33 |
| MAs | MA(5) : | 0.51 |
MA(20) : | 0.5 |
| MA(100) : | 1.04  |
MA(250) : | 11 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 75.2 |
D(3) : | 56.2 |
| RSI | RSI(14): 57.8 |
|||
| 52-week | High : | 25.69 | Low : | 0.33 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FGEN ] has closed above the upper band by 6.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 71.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 97 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.59 - 0.59 | 0.59 - 0.59 |
| Low: | 0.49 - 0.5 | 0.5 - 0.5 |
| Close: | 0.55 - 0.55 | 0.55 - 0.56 |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Fri, 01 Dec 2023
Is FibroGen Inc (FGEN) a Good Choice in Biotechnology Friday? - InvestorsObserver
Fri, 24 Nov 2023
A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN) - Simply Wall St
Tue, 07 Nov 2023
FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript - Yahoo Finance
Mon, 23 Oct 2023
FibroGen to Report Third Quarter 2023 Financial Results - Yahoo Finance
Wed, 18 Oct 2023
Insiders Could Have Profited By Holding onto FibroGen Shares Despite 18% Drop - Simply Wall St
Wed, 30 Aug 2023
FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23% - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 98 (M) |
| Shares Float | 85 (M) |
| Held by Insiders | 5.8 (%) |
| Held by Institutions | 83.2 (%) |
| Shares Short | 13,510 (K) |
| Shares Short P.Month | 10,510 (K) |
| EPS | -3.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.61 |
| Profit Margin | -189.9 % |
| Operating Margin | -126.8 % |
| Return on Assets (ttm) | -30 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 155.1 % |
| Gross Profit (p.s.) | -1.62 |
| Sales Per Share | 1.57 |
| EBITDA (p.s.) | -2.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -349 (M) |
| Levered Free Cash Flow | -192 (M) |
| PE Ratio | -0.21 |
| PEG Ratio | 0 |
| Price to Book value | -0.4 |
| Price to Sales | 0.39 |
| Price to Cash Flow | -0.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|